282 related articles for article (PubMed ID: 21109842)
21. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation.
de Leon J
CNS Spectr; 2006 Mar; 11(3 Suppl 3):8-12. PubMed ID: 17760224
[No Abstract] [Full Text] [Related]
22. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients.
Ieiri I; Yamada S; Seto K; Morita T; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Pharmacopsychiatry; 2003 Sep; 36(5):192-6. PubMed ID: 14571354
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of pharmacogenetics in psychiatry].
Skrętkowicz J; Barańska M; Rychlik-Sych M
Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacogenetics and tailored drug treatment in schizophrenia].
Andreassen OA; Steen VM
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
[TBL] [Abstract][Full Text] [Related]
25. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
[TBL] [Abstract][Full Text] [Related]
26. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
27. Cytochromes and psychotropic drug interactions.
Bates GD; Van Woerkom AE
Br J Psychiatry; 1996 Nov; 169(5):670. PubMed ID: 8932910
[No Abstract] [Full Text] [Related]
28. Pharmacogenetics of classical and new antipsychotic drugs.
Otani K; Aoshima T
Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
[TBL] [Abstract][Full Text] [Related]
29. The association between cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: a retrospective follow-up study.
Mulder H; Wilmink FW; Belitser SV; Egberts AC
J Clin Psychopharmacol; 2006 Apr; 26(2):212-5. PubMed ID: 16633157
[No Abstract] [Full Text] [Related]
30. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
Quaranta S; Dupouey J; Colle R; Verstuyft C
Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
[TBL] [Abstract][Full Text] [Related]
31. Implementation of CYP2D6 genotyping in psychiatry.
Loovers HM; van der Weide J
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1065-77. PubMed ID: 19572825
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics of psychotropic drug response.
Malhotra AK; Murphy GM; Kennedy JL
Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
[TBL] [Abstract][Full Text] [Related]
33. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?
Haffen E; Vandel P; Paintaud G; Broly F; Vandel S; Bonin B; Bizouard P; Sechter D; Bechtel PR
Eur J Clin Pharmacol; 2000; 55(11-12):877-9. PubMed ID: 10805068
[No Abstract] [Full Text] [Related]
36. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?
Laika B; Leucht S; Heres S; Steimer W
Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetic considerations in the treatment of psychiatric disorders.
Lohoff FW; Ferraro TN
Expert Opin Pharmacother; 2010 Feb; 11(3):423-39. PubMed ID: 20102306
[TBL] [Abstract][Full Text] [Related]
38. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
Preskorn SH
J Psychiatr Pract; 2010 May; 16(3):177-82. PubMed ID: 20485106
[TBL] [Abstract][Full Text] [Related]
39. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
40. Where are we today with personalized medicine?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2012 Nov; 50(11):11-3. PubMed ID: 23066831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
